METASTATIC CASTRATE RESISTANT PROSTATE CANCER
Clinical trials for METASTATIC CASTRATE RESISTANT PROSTATE CANCER explained in plain language.
Never miss a new study
Get alerted when new METASTATIC CASTRATE RESISTANT PROSTATE CANCER trials appear
Sign up with your email to follow new studies for METASTATIC CASTRATE RESISTANT PROSTATE CANCER, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Immune cells armed with cancer-seeking antibodies tested in advanced cancers
Disease control Recruiting nowThis study tests a new treatment for people with metastatic breast or prostate cancer that has stopped responding to standard therapies. Participants receive infusions of their own immune cells that have been armed with a special antibody to help them find and attack cancer cells…
Matched conditions: METASTATIC CASTRATE RESISTANT PROSTATE CANCER
Phase: PHASE1, PHASE2 • Sponsor: University of Virginia • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Could a constipation drug slow cancer growth? new trial seeks answers
Disease control Recruiting nowThis study tests if axelopran, a drug used for opioid-induced constipation, can slow tumor growth in people with advanced breast, lung, pancreas, or prostate cancer. About 34 adults whose cancer has worsened after standard treatment will take axelopran daily for up to a year. Res…
Matched conditions: METASTATIC CASTRATE RESISTANT PROSTATE CANCER
Phase: PHASE2 • Sponsor: HealthPartners Institute • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Engineered immune cells take on Hard-to-Treat prostate cancer
Disease control Recruiting nowThis early-phase trial is testing a new treatment called TmPSMA-02 for men with metastatic castrate-resistant prostate cancer that has progressed after standard therapies. The treatment uses the patient's own immune cells (T cells) that are genetically modified to recognize and a…
Matched conditions: METASTATIC CASTRATE RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: University of Pennsylvania • Aim: Disease control
Last updated Jun 27, 2026 08:06 UTC
-
Could custom doses of prostate cancer radiation be safer and stronger?
Disease control Recruiting nowThis study tests whether giving a personalized dose of the drug 177Lu-PSMA-617 (Pluvicto) based on kidney function is safer and allows higher doses than the standard fixed dose. Sixty men with metastatic castration-resistant prostate cancer will receive either personalized or fix…
Matched conditions: METASTATIC CASTRATE RESISTANT PROSTATE CANCER
Phase: PHASE1 • Sponsor: Jean-Mathieu Beauregard • Aim: Disease control
Last updated Jun 26, 2026 14:37 UTC